Skip to content
HowShorted

Zynerba Pharmaceuticals, Inc. short interest in 2022

In 2022, Zynerba Pharmaceuticals, Inc.'s disclosed short interest ran from 6.69% of shares outstanding on 14 Jan 2022 to 1.20% on 15 Dec 2022, a change of -5.49 percentage points. The year's high was 6.69% on 14 Jan 2022 and its low 0.92% on 31 Oct 2022, averaging 2.56% across 23 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 7.47 days on 29 Apr 2022. Full history: Zynerba Pharmaceuticals, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023

Aggregate net short position time series for Zynerba Pharmaceuticals, Inc. in 2022

2022 in figures

Start of year
6.69% (14 Jan 2022)
End of year
1.20% (15 Dec 2022)
Change
-5.49 pp
High
6.69% (14 Jan 2022)
Low
0.92% (31 Oct 2022)
Average
2.56%
Highest days to cover
7.47 (29 Apr 2022)
SEC filings marked
8

Every report in 2022

Zynerba Pharmaceuticals, Inc. short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 20226.69%3.79
31 Jan 20225.06%2.57
15 Feb 20224.65%3.49
28 Feb 20224.23%5.70
15 Mar 20224.01%4.7410-K filed, results (8-K)
31 Mar 20223.20%2.73
14 Apr 20223.19%5.20
29 Apr 20223.17%7.47
13 May 20222.12%2.71
31 May 20222.01%3.2610-Q filed, results (8-K)
15 Jun 20222.23%1.00
30 Jun 20222.21%2.53
15 Jul 20221.94%2.35
29 Jul 20222.07%1.93
15 Aug 20221.46%1.2110-Q filed, results (8-K)
31 Aug 20221.57%1.53
15 Sep 20221.75%2.09
30 Sep 20221.34%1.40
14 Oct 20221.15%1.98
31 Oct 20220.92%2.76
15 Nov 20221.24%2.1010-Q filed, results (8-K)
30 Nov 20221.52%1.79
15 Dec 20221.20%2.37

See also: Zynerba Pharmaceuticals, Inc.'s full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.